| Field | Specification |
|---|---|
| Target | |
| Alternative names | Fibroblast growth factor receptor 4;FGFR-4;2.7.10.1;CD334;FGFR4;JTK2, TKF; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human FGFR4 recombinant protein (Position: L22-H206). Human FGFR4 shares 86% and 84% amino acid (aa) sequences identity with mouse and rat FGFR4, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets fibroblast growth factor receptor 4 (gene FGFR4) in human samples and is validated for IHC and Western blot. The predicted molecular weight is 88.0 kDa, and the supplier reports an observed band at about 100 kDa.
Fibroblast growth factor receptor 4 (FGFR4) is a receptor tyrosine kinase that, together with the coreceptor β-Klotho, mediates FGF19 signaling in the liver. It regulates bile acid synthesis and aspects of lipid and glucose metabolism, and it also contributes to muscle development. FGFR4 is studied in metabolism and in liver cancer.
| Target | Fibroblast growth factor receptor 4 (gene FGFR4; UniProt P22455, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 88.0 kDa |
| Observed MW | 100 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human) |
Samples with a confirmed band (WB): human HeLa cells, human PANC cells, human SGC cells, human COLO320 cells, human SW620 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Recombinant human FGFR4 fragment (Leu22–His206), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 86% and 84%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places fibroblast growth factor receptor 4 in the cell membrane, endosome and endoplasmic reticulum. Tissue expression noted by UniProt (human): Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Braun Marcin et al. (2024) FGFR4-driven plasticity in breast cancer progression and resistance to therapy. British Journal of Cancer. 10.1038/s41416-024-02658-y
